Find an Article

Filter articles

Applied Filters

Showing 141 to 150 of 324 results

New technologies, old framework: maximising IP protection for 3D printing in the life sciences

US05-01-2017Arlene Chow and Nitya Anand

IP law has yet to catch up with the technological capabilities of 3D printing, but by taking pre-emptive action, companies can maximise their IP protection under the current legal framework. Arlene Chow and Nitya Anand of Hogan Lovells report.

Life sciences transactions: look before you leap

US06-12-2016Karen Mangasarian and Ryan Murphey

Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain.

Patenting genes: how do India and the US compare?

India, US17-11-2016Swarup Kumar

India’s position on patenting genes borrows heavily from that of the US, but will the status quo change? Swarup Kumar of Remfry & Sagar reports.

Doubling up: biotech patent examination in Brazil

Brazil25-10-2016Marcelo Oliveira de Souza and Antonio Alexandre Moura dos Santos

Two bodies are responsible for examining biotech patent applications in Brazil, but this approach causes problems, as Marcelo Oliveira de Souza and Antonio Alexandre Moura dos Santos of Di Blasi, Parente & Associados report.

IP service providers: a more cost-effective solution post M&A?

International18-10-2016Melissa Pillote

With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.

Keeping a clear head: Mexico’s rules on alcohol labels

Mexico17-10-2016Daniel Sanchez and Victor Ramirez

Mexico has introduced new rules for labelling alcoholic beverages in an effort to fight abuse of the ‘demon drink’, as Daniel Sanchez and Victor Ramirez of Olivares report.

Technology transfer: A smart way of working

International14-10-2016Montserrat González-Álvarez

‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.

Life Technologies v Promega: the long tentacles of infringement

US12-10-2016Sandra Kuzmich and Russell Garman

Global companies are watching a pending life sciences patent case at the US Supreme Court because of its potential impact both within and outside US borders, as Sandra Kuzmich and Russell Garman of Frommer Lawrence & Haug explain.

Working together wisely

International12-10-2016Oliver Laing and Tony Proctor

In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.

What drives the urge to merge?


There is some debate about whether the ‘patent cliff’ or the need to innovate is driving M&A activity in the pharmaceutical industry, where billions of dollars have been spent in the past few years, as LSIPR finds out.

Showing 141 to 150 of 324 results